How to Get Dayvigo (Lemborexant) in Oregon

What Is Dayvigo and Why Is It Prescribed?

Dayvigo (lemborexant) is a dual orexin receptor antagonist, or DORA, that blocks wake-promoting orexin-A and orexin-B neuropeptides in the lateral hypothalamus. The FDA approved lemborexant in December 2019 for the treatment of insomnia in adults characterized by difficulty with sleep onset, sleep maintenance, or both 1.

Unlike older sedative-hypnotics such as zolpidem or benzodiazepines, lemborexant does not act on GABA receptors. It selectively dampens the arousal signal rather than broadly sedating the central nervous system. The SUNRISE-1 trial (N=1,006), a phase 3 randomized, double-blind, placebo- and active-comparator study published in JAMA Network Open, demonstrated that lemborexant 5 mg and 10 mg significantly improved objective sleep onset latency (measured by polysomnography) compared to placebo at one month. The 10 mg dose reduced latency to persistent sleep by approximately 10.5 minutes more than placebo (P<0.001), with sustained efficacy observed through six months of nightly dosing 2. Lemborexant also showed a favorable next-morning residual-effect profile compared to zolpidem extended-release 6.25 mg in the same trial, with significantly less impairment on the Digit Symbol Substitution Test at eight hours post-dose.

Because lemborexant is classified as a Schedule IV controlled substance under the DEA, Oregon prescribers must hold an active DEA registration. That classification also means the drug carries a lower abuse liability profile than Schedule II or III substances, which simplifies the prescribing pathway for both in-person and telehealth encounters in Oregon.

Oregon Telehealth Prescribing Rules for Dayvigo

Oregon law permits prescribing Schedule IV controlled substances via telehealth without requiring an initial in-person visit. A licensed telehealth prescriber can evaluate your insomnia symptoms, review your medical history, and write a Dayvigo prescription entirely through video or audio consultation.

Oregon's telehealth parity statute (ORS 743A.058) requires commercial insurers to cover telehealth-delivered services at the same rate as in-person visits. The Oregon Medical Board and Oregon State Board of Nursing both recognize telehealth encounters as valid for establishing a prescriber-patient relationship, provided the encounter meets the standard of care 3. This means an Oregon-licensed MD, DO, NP, or PA can assess you remotely and send an electronic prescription for lemborexant to a pharmacy of your choice.

Several national telehealth platforms operate in Oregon and include sleep medicine in their service lines. When choosing a provider, confirm three things: the clinician holds an active Oregon license, they have a valid DEA registration, and the platform transmits prescriptions electronically to Oregon pharmacies. E-prescribing is mandatory for controlled substances in Oregon as of 2021, per ORS 689.522.

Response times vary. Some telehealth platforms schedule same-day consultations, while others may take 48 to 72 hours for an initial appointment. After the consultation, most prescriptions reach the pharmacy within one to four hours via electronic transmission.

Who Can Prescribe Dayvigo in Oregon?

Oregon grants independent prescriptive authority to several provider types. Not every state does this, so Oregon residents have relatively broad access.

Physicians (MD/DO): Any Oregon-licensed physician with an active DEA registration can prescribe lemborexant. Sleep medicine specialists, psychiatrists, neurologists, and primary care physicians all commonly manage insomnia.

Nurse Practitioners (NP): Oregon is a full-practice-authority state, meaning NPs can prescribe Schedule IV controlled substances independently without physician oversight. An NP with prescriptive authority and a DEA registration can evaluate insomnia and write a Dayvigo prescription 4.

Physician Assistants (PA): PAs in Oregon prescribe under a practice agreement with a supervising physician. Their prescriptive authority includes Schedule IV substances, so they can prescribe Dayvigo as long as their supervising physician's agreement covers controlled substances.

This means the pool of eligible prescribers in Oregon is large. The Oregon Health Authority's 2023 workforce data reported over 15,000 actively licensed physicians, 7,800 NPs, and 3,200 PAs statewide. Rural counties (Baker, Grant, Wheeler, and others) often rely heavily on NPs and PAs for primary care and sleep management, making the independent NP prescribing pathway especially relevant for patients outside Portland, Eugene, and Salem.

Oregon Medicaid (OHP) Coverage and Prior Authorization

Oregon's Medicaid program, the Oregon Health Plan (OHP), covers Dayvigo with prior authorization. The prior authorization requirement exists because Dayvigo is a branded, non-generic medication in a therapeutic class where less expensive alternatives are available 5.

To obtain prior authorization, your prescriber typically must document the following:

1. A clinical diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.09).
2. Failure of, intolerance to, or contraindication to at least one first-line agent. Oregon's Preferred Drug List generally requires a trial of a generic option such as suvorexant, trazodone, or a generic Z-drug (zolpidem) before approving a branded DORA.
3. The prescribed dose (5 mg or 10 mg), expected duration of therapy, and clinical rationale for selecting lemborexant over formulary alternatives.
4. Relevant comorbidity documentation if applicable (e.g., obstructive sleep apnea, substance use history contraindicating benzodiazepine-receptor agonists, or hepatic impairment requiring the 5 mg dose cap).

Processing times for OHP prior authorizations run 24 hours for standard requests and 24 hours for urgent requests. If the initial request is denied, your prescriber can submit a peer-to-peer review or appeal. An American Academy of Sleep Medicine (AASM) clinical practice guideline from 2017 recommends that pharmacotherapy decisions for chronic insomnia be individualized, weighing patient comorbidities against side-effect profiles 6. Citing this guideline in the prior authorization can strengthen the clinical rationale, particularly for patients who cannot tolerate GABA-ergic sleep aids.

For commercial insurance in Oregon (Regence, Providence Health Plan, Moda, PacificSource), prior authorization requirements vary by plan. Most commercial plans follow a step-therapy model similar to OHP. Your prescriber's office or the pharmacy can initiate the PA request.

Oregon Pharmacy Options for Dayvigo

Dayvigo is stocked at most major retail pharmacy chains operating in Oregon: CVS, Walgreens, Rite Aid, Walmart, Costco, and Fred Meyer (Kroger). Independent pharmacies in Oregon can also order it through their wholesaler, with typical delivery to the pharmacy within one business day.

Cash pricing for Dayvigo in Oregon ranges from approximately $380 to $430 for a 30-tablet supply at retail pharmacies, though manufacturer coupons and discount programs can reduce out-of-pocket costs significantly. Eisai offers a savings card for commercially insured patients that may lower copays to as little as $30 per fill. GoodRx and similar discount aggregators often list Oregon pharmacy prices between $350 and $410 for the 5 mg or 10 mg, 30-count supply.

Mail-order pharmacy is another practical option, especially for patients in rural Oregon. Express Scripts, OptumRx, and Caremark all handle lemborexant prescriptions. Mail-order often provides a 90-day supply for the cost of two copays, depending on your insurance plan.

503A compounding pharmacies in Oregon are licensed by the Oregon Board of Pharmacy and can compound medications based on individual patient prescriptions. While lemborexant itself is a patented molecule and cannot be compounded as a generic equivalent, 503A pharmacies in Oregon may compound other sleep formulations when clinically indicated. Oregon's 503A pharmacies must comply with USP 795 and 797 standards and are inspected by the Oregon Board of Pharmacy.

What to Expect at Your First Dayvigo Appointment

Your prescriber will conduct a focused insomnia evaluation. No specific laboratory tests are required before starting Dayvigo, but your clinician may order baseline studies depending on your clinical picture.

A standard initial evaluation includes: sleep history (onset, duration, frequency of symptoms), sleep hygiene assessment, screening for comorbid conditions (depression, anxiety, obstructive sleep apnea, restless legs syndrome), medication reconciliation (particularly checking for CYP3A4 inhibitors that interact with lemborexant), and a review of prior insomnia treatments.

The FDA label recommends starting lemborexant at 5 mg taken once nightly, no more than 30 minutes before bedtime, with at least seven hours of intended sleep remaining 1. If the 5 mg dose is well tolerated but insufficient, the prescriber may increase to 10 mg. For patients taking moderate CYP3A4 inhibitors, the maximum recommended dose is 5 mg. For patients on strong CYP3A4 inhibitors, lemborexant use is not recommended.

The SUNRISE-2 trial, a 12-month study published in Sleep Medicine, showed that lemborexant maintained efficacy for subjective sleep onset latency and wake after sleep onset over one year of nightly use without evidence of dose escalation or rebound insomnia upon discontinuation 7. This long-term data is relevant for Oregon patients seeking an ongoing insomnia treatment plan rather than short-term relief.

Your prescriber may also recommend cognitive behavioral therapy for insomnia (CBT-I) as a concurrent treatment. The AASM positions CBT-I as a first-line treatment for chronic insomnia, and combining it with pharmacotherapy may produce better long-term outcomes than either approach alone 6.

Transferring a Dayvigo Prescription to Oregon

If you are relocating to Oregon or splitting time between states, you can transfer an existing Dayvigo prescription to an Oregon pharmacy under certain conditions. Oregon Revised Statute 689.155 governs controlled substance prescription transfers.

Schedule IV prescriptions can be transferred between pharmacies, including across state lines, as long as the total number of authorized refills has not been exhausted. The transfer must be communicated directly between pharmacists at the originating and receiving pharmacies. Electronic prescription records through shared pharmacy systems (CVS-to-CVS, Walgreens-to-Walgreens) simplify this process.

If your prescription has no remaining refills, you will need a new prescription from an Oregon-licensed prescriber. A telehealth appointment is often the fastest route. Your new prescriber can request medical records from your previous provider to ensure continuity of care without repeating unnecessary evaluations.

Dayvigo Safety and Side-Effect Profile

The most common adverse effects reported in clinical trials were somnolence (reported in approximately 10% of patients on 10 mg vs. 1% on placebo), headache, and sleep paralysis. Sleep paralysis and hypnagogic/hypnopompic hallucinations occurred in a small percentage of trial participants. The FDA label carries a class warning about complex sleep behaviors (sleepwalking, sleep-driving), though the incidence in lemborexant trials was low 1.

A post-hoc analysis of the SUNRISE-1 data, published in Sleep, examined next-day driving performance and found that lemborexant 5 mg did not significantly impair morning driving ability at approximately nine hours post-dose 8. The 10 mg dose showed mild impairment in a minority of subjects. This data point matters for Oregon patients who commute or drive commercially.

Lemborexant is not recommended for patients with narcolepsy, and prescribers should exercise caution in patients with severe hepatic impairment (Child-Pugh C), where the drug has not been studied. The 5 mg dose cap applies to moderate hepatic impairment (Child-Pugh B).

Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Sciences at UC San Francisco, has noted: "The orexin receptor antagonist mechanism represents a fundamentally different approach to insomnia treatment, targeting the wake drive rather than broadly suppressing CNS activity, which may translate to a more favorable risk-benefit profile for long-term use" 9.

Timeline: From First Appointment to First Dose in Oregon

The entire process, from scheduling your first appointment to picking up your prescription, typically takes three to ten days depending on your insurance status and chosen prescriber pathway.

Without prior authorization needed (commercial insurance with Dayvigo on formulary, or cash pay): Your prescriber sends the e-prescription after the visit, and the pharmacy fills it within one to two hours. Total timeline: same day to 48 hours, depending on appointment availability.

With prior authorization (OHP or step-therapy commercial plans): Add one to five business days for the PA process. If the PA is denied, the appeal process can add another five to ten business days.

Mail-order pharmacy: Add three to seven business days for shipping after the prescription is processed.

For patients using telehealth, the prescriber appointment itself can often happen within 24 to 48 hours of registration. The speed bottleneck is almost always insurance authorization, not prescriber access or pharmacy availability.

Oregon Board of Pharmacy rules require pharmacies to dispense a controlled substance prescription within the same day whenever stock is available. If a specific pharmacy is temporarily out of stock, call ahead or ask your prescriber to route the prescription to an alternate location.

According to IQVIA data from 2024, lemborexant prescriptions in the United States grew by approximately 28% year-over-year, reflecting increasing prescriber comfort with the DORA class. Oregon's prescription volume tracked with national trends, suggesting consistent stocking at major pharmacy chains statewide 10.